Sponsors
MERCK SHARP & DOHME (MSD)
PRINCIPLE OF �HUMANS FIRST� DETERMINES MSD VISION
A global leader in healthcare products, Merck & Co. Inc. with its vision grounded on the principle of �Humans First,� was established in 1891 in the United States of America. Its roots go further back in history to a moderate pharmaceutical warehouse which was founded by pharmacist E. Merck in 1668 and developed through generations. Carrying this long-established tradition to the 20th Century with significant success, Merck & Co. Inc. merged with Sharp & Dohme in 1953 to double its strength in scientific research, and started providing services under the name Merck Sharp & Dohme (MSD) in all countries except the USA, where its original name was maintained.
Pfizer
Pfizer Inc, founded in 1849, is dedicated to better health and greater access to healthcare for people. Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines and global leadership in corporate responsibility.

Every day Pfizer helps 38 million patients, employ more than 100,000 colleagues, utilize the skills of more than 12,000 medical researchers to treat and prevent illnesses�adding both years to life, and life to years. Pfizer�s pipeline of new medicines is the largest in the pharmaceutical industry, focusing on a broad range of unmet medical needs spanning 11 Therapeutic areas. Pfizer invests more than $7 billion annually in the research and development of new products across more therapeutic areas than any other company in our industry. Relying on the strength of our pipeline and scientific talent, Pfizer has generated a steady stream of breakthroughs over the years, and our researchers continue to work around the clock and around the globe to ensure the best medicines for our patients in the years to come.

Pfizer in Turkey
Pfizer Turkey has been operating in pharmaceutical sector in Turkey since 1957. Funded completely with foreign capital and employing more than 1,100 individuals, Pfizer Turkey manufactures 83% of the products it presents to the Turkish medical community in Turkey. Sixteen percent of Pfizer�s manufacturing is conducted in Central and Eastern Europe, including EU countries, the Middle East and Far East and products are exported to 22 countries in total. With its revenues of 472.9 million YTL according to IMS data from December 2021, Pfizer Turkey ranks fifth in the Turkish pharmaceutical industry.

With its R&D investment of $3 million in Turkey, Pfizer is serving the medical community with products that target several important therapeutic areas such as the Central Nervous System, Infectious Diseases, Cardiology, Oncology, Urology and Ophtalmology.In addition to serving the Turkish medical community with innovative drugs, one of the most important goals of Pfizer Turkey is to serve public health. In line with this goal, it develops several training programs in collaboration with academic and scientific communities, supports scientific symposia and clinical research and provides research support awards and scholarships

SCHERING PLOUGH
Incorporated in 1928 in the United States, Schering-Plough was initially a subsidiary of Schering AG, a German-based pharmaceutical company. During World War II, the company demerged from the parent company in Germany and was nationalized by the U.S. government. In 1952, the U.S. government seceded from the company management and offered the company to the public.

In 1971, it merged with Plough, a company located in Memphis, Tennessee operating in consumer products, to create Schering-Plough Corporation .

The company is now headquartered in Kenilworth, New Jersey, in the United States. With production facilities and 30,000 employees in 25 countries and offices in 50 countries world-wide, Schering-Plough is a well-established global pharmaceutical company offering prescription and over-the-counter drugs and animal health products in more than 125 countries.

WALL STREET INSTITUTE
The Wall Street Institute was founded in 1972. The school has over 400 centers in 28 countries and teaches English to 200.000 students per year.
The Turkish branch of The Wall Street Institute first started to give its unique education in February of 2021.

By 2021 the school had 9 centers in Turkey: �stanbul �i�li, Taksim, Bak�rk�y, Erenk�y and Caddebostan; Ankara K�z�lay; Eski�ehir Anatolia Univercity Campus, �zmit and Ankara Ostim. Wall Street Institue has 10.000 students annually and provides education to over 500 companies.

The most significant difference in the educatioanal programme of The Wall Street Institute is, its ability to be customized to the needs of the indidvidual. The uniqe method of WSI in Corporate and individual training allows us to give a �guaranty� that the student will learn.

The several characterisrics of the sytem ;


  1. FLEXIBLE HOURS: At The Wall Street Institute the hours of lessons are not constant. According to your personal programme you can set your training hours It is not dependent on a class.
  2. MAXIMUM OF 4 STUDENTS IN A CLASS: There is a maximum of 4 students in a class. Each with the same level as you and all the teachers are native speakers.
  3. YOU SPEAK ENGLISH FROM FIRST DAY: The WSI method allows you to speak from the first day of your education. Thus, the most diffucult step in learning English is exceeded from the first day.
  4. GUARANTEED EDUCAT�ON: WSI guarantees the students to reach their goals if they commit t� 4 hours a week. The school even certificates this giving a money-back guaranty.
  5. QUANTITAYIVELY MEASURED IMPROVEMENT: Through out the students educatioan, WSI presents reports about your grammer, vocabulary, reading-writng skills, listening-understanding skills of your English. Thus you can follow the development of your success with the teacher.

  6. PERSONAL TRAINING SPEED: Independent to the other students you can study at your own learning speed.

  7. START TO LEARN IMMEDIATELY: The Wall Street Institute is tailored to individual needs. You do not need to wait for the others to open/find a class at your level.

If you need more informatioan about Wall Street Institute you can call 0 800 211 61 71 or 0 212 233 12 12 or contact us at www.wsi.com.tr.


Contact for information:
0 800 211 61 71 - 0212 233 12 12 [email protected]

 
YAPI ICF KAISER
The firm established as Yap�-ICF Kaiser Engineering and Consultancy Inc. on 9th October 1997, has commenced to provide the Consultancy and Supervision Services for the Bursa Light Rail Transit System Project on 5th December 1997. 17 km long section of the Bursa LRT system, known as Section A has commenced revenue operations in September 2021 and the construction of the 5 km long Section B has started in June 2021. Currently studies are being conducted to continue with the extension towards west for another 7 km and the project is already included in the investment plan.

The services provided in Bursa Light Rail Transit System Project include contract management, construction control and supervision, various engineering studies, operations and maintenance support and liaison with different parties including the loan agencies.

Besides the consultancy and supervision services Contract for Bursa Light Rail System, Yap�-ICF Kaiser has been providing some services in various engineering studies.

CAPABILITIES
Over the last 10 years Yap� ICF Kaiser has proven itself to be a well-established and strong firm that it capable to establish good relations with banks and clients and manage an international projects of large scale. Its well experienced staff can provide services in various areas, both in national and international projects. The services that can be provided are briefly listed below:
  • Consultancy, engineering and supervision services for Light Rail System, Metro, Railway projects, tunnels and bridges
  • Construction, engineering and supervision services for water, wastewater treatment projects and irrigation projects.
  • Support in studies like EIA, environmental due diligence, transportation planning, urban planning and tunnel ventilation studies etc.
  • Structural studies including seismic analysis, structural reinforcement and structural due diligence studies.
  • Consultancy, engineering, supervision services as well as construction of buildings, facilities and related sites.
  • Pipeline projects.
  • Contract administration, including programming, cost analysis and related studies.
  • Preparation of tender documents and specifications for the client.
    •  

     
    TOREADOR TURKEY
    Toreador Resources is a well-rounded independent oil and gas company. An international explorer and producer, the company has a promising inventory of prospects in France, Romania and Turkey.

    In early 2021, Toreador sold its U.S. mineral and royalty assets, which repositioned the company as an international explorer and developer. The sale empowered the company to take advantage of higher-potential exploration opportunities overseas that create greater long-term value for investors.

    Toreador retains a U.S. presence through its principally nonoperated working-interest ownership in about 900 oil and gas exploration and development wells primarily in five states: Kansas, Louisiana, New Mexico, Oklahoma and Texas. The company plans to continue its participation in select domestic exploratory wells and pursue nonoperated working-interest acquisition opportunities.
     

     
    BRISTOL-MYERS SQUIBB
    Bristol-Myers Squibb is a leading provider of medicines to fight cancer, cardiovascular and infectious diseases -- including HIV/AIDS -- and serious mental illness. Since our company�s founding in upstate New York in 1887, we have grown to become a global health care leader. In our world-class research and development facilities -- located in New Jersey, Connecticut and elsewhere around the globe -- we�re looking for new and better treatments for cancer, diabetes, HIV/AIDS and other serious illnesses and conditions. Augmenting our internal R&D capabilities, Bristol-Myers Squibb has an extraordinary history of successful partnerships to develop and deliver important new medicines to people who need them worldwide.
     

     
    GNC LiveWell